ClinicalTrials.gg
RecruitingNCT07622329Updated Nov 17, 2026

A Clinical Study to Evaluate JCXH-213 in the Treatment of Adults With Primary Immune Thrombocytopenia

A Phase 1 interventional study of JCXH-213 in Thrombocytopenic Purpura, Immune, sponsored by The General Hospital of Western Theater Command. Recruiting at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by The General Hospital of Western Theater Command · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2026; still recruiting 5 months later.
Updated Nov 17, 2026Now RecruitingFirst site in China+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
4
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 187 studies in Purpura, Thrombocytopenic, Idiopathic with a site in China — 84 open to participants now, 94 under way, 12 of them phase 3. Purpura, Thrombocytopenic, Idiopathic · China.

Planned enrollment
160th of 169
4 · median 60
Started
2026
with 20 others
Phase 1
21 of 187
12 open now
Primary completion
2026-09
later than 46 of 93 live
Registered
179th of 187
by date

Among the 187 studies in Purpura, Thrombocytopenic, Idiopathic with a site in China, this one is the 160th largest by planned enrollment of the 169 interventional ones that give a count, is one of 21 that started in 2026, is one of 21 in phase 1, reaches primary completion later than 46 of the 93 other live ones, and was the 179th registered.

Purpura, Thrombocytopenic, Idiopathic

505 studies on the registry are indexed under Purpura, Thrombocytopenic, Idiopathic; 160 are open to participants now.

Browse Purpura, Thrombocytopenic, Idiopathic studies →

Open to participants now

84 of the 187 studies in Purpura, Thrombocytopenic, Idiopathic with a site in China are open now. Recruiting first, the newest first:

78 more — sign in →

All 84 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 104 Purpura, Thrombocytopenic, Idiopathic studies recruiting now, 49 (47%) set no upper age limit and 43 (41%) stop at 75 or younger; 27 take children under 18; 4 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 187 studies in Purpura, Thrombocytopenic, Idiopathic with a site in China, or all of them as a file.
02

Study summary

This is an open-label, single-arm, dose-escalation study designed to evaluate the safety, tolerability, recommended subsequent dose, pharmacokinetic profile, and preliminary efficacy of JCXH-213 in adult patients with primary immune thrombocytopenia (ITP) who are refractory or relapsed after treatment with corticosteroids and second-line therapies.

The study consists of a screening period, treatment period, end-of-treatment visit, safety follow-up, and study withdrawal visit. Two dose groups are planned: 2 mg and 4 mg, with 2 patients to be enrolled in each dose group. During the treatment period, JCXH-213 at the assigned dose will be administered once every other day for a total of 7 doses. Assessments for safety and efficacy will be conducted according to the study schedule. After the last dose, patients will undergo an end-of-treatment visit and safety follow-up until the end of the study.

03

Conditions studied

  • Thrombocytopenic Purpura, Immune

Keywords

  • JCXH-213
  • ITP
  • Primary Immune Thrombocytopenia (ITP) Refractory or Relapsed to Corticosteroids and Second-line Therapies
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Voluntarily sign the form (ICF) and be expected to complete the follow-up visits and treatment required by the study protocol.
  2. Age ≥ 18 years and ≤ 65 years at screening, male or female.
  3. Clinical diagnosis of primary immune thrombocytopenia (ITP) for no less than 3 months, according to the American Society of Hematology 2011 Evidence-Based Practice Guideline (Neunert et al. 2011) or the International Consensus Report on the Investigation and Management of Primary Immune Thrombocytopenia (Provan et al. 2010), as applicable.

    Failure (ineffective, loss of maintenance of response, or relapse) of therapy and failure (ineffective, loss of maintenance of response, or relapse) or intolerance to at least one ITP therapy.

  4. At least one second-line ITP therapy includes: rituximab and/or recombinant human thrombopoietin (rhTPO, e.g., TPO), thrombopoietin receptor agonists (TPO-RA, e.g., eltrombopag, hetrombopag, avatrombopag, romiplostim).

    Ineffectiveness is defined as count \< 30 × 10⁹/L after receiving the following treatments:

    Rituximab: 375 mg/m² once weekly for 4 doses; rhTPO: 300 U/kg/day for more than 14 days; Eltrombopag: 75 mg/day for more than 28 days; Hetrombopag: 7.5 mg/day for more than 28 days; Avatrombopag: 60 mg/day for more than 28 days; Romiplostim: up to a maximum weekly dose of 10 μg/kg for more than 28 days.

  5. Platelet count \< 30 × 10⁹/L within 48 hours prior to the first dose of study drug (at least two consecutive platelet counts \< 30 × 10⁹/L, at least 1 day apart, during screening and/or prior to first dose).
  6. (ECOG) performance status score of 0-2.
  7. Patients receiving stable-dose maintenance therapy, including corticosteroids (not exceeding 0.5 mg/kg/day prednisone or equivalent) or thrombopoietin receptor agonists, may be enrolled, provided that the patient is on only one concomitant medication with stable dose and frequency, and the concomitant medication has been stable for at least 4 weeks prior to the first infusion of study drug.
  8. Adequate organ function, meeting the following laboratory criteria:

    Coagulation function:

    (APTT) ≤ 1.5 × (ULN) Prothrombin time (PT) ≤ 1.5 × ULN

    Liver function:

    (ALT) and aspartate aminotransferase (AST) ≤ 2.5 × ULN Total ≤ 1.5 × ULN, unless documented Gilbert's syndrome Patients with Gilbert-Meulengracht syndrome may be included if total bilirubin ≤ 3.0 × ULN and direct bilirubin ≤ 1.5 × ULN

    Renal function:

    Serum creatinine ≤ 1.5 × ULN, or ≥ 60 mL/min (Cockcroft-Gault formula; see Appendix 1)

    Hematology (without blood transfusion, platelet transfusion, or growth factor use within 7 days prior to screening hematology assessment):

    ≥ 80 g/L (ANC) ≥ 1.0 × 10⁹/L Absolute lymphocyte count (LY) ≥ 0.5 × 10⁹/L

    Cardiopulmonary function:

    (LVEF) ≥ 45% Oxygen saturation ≥ 91% without supplemental oxygen

  9. Female patients of must have a negative pregnancy test at screening. Any male or female patient of childbearing potential must agree to use effective methods from the time of signing the ICF through at least 6 months after the last infusion of JCXH-213.

Female patients not of childbearing potential must meet at least one of the following criteria:

Have undergone hysterectomy, bilateral salpingectomy, or bilateral oophorectomy; Medically confirmed (at least 12 consecutive months of amenorrhea without pathological or physiological cause, with reproductive status assessed by hormone levels if necessary).

Exclusion criteria

Exclusion Criteria

  1. Diagnosis of hemolytic anemia, any secondary or hereditary thrombocytopenic disorders, including leukemia, lymphoma, multiple myeloma, aplastic anemia, myelodysplastic syndrome, Evans syndrome, common variable immunodeficiency, systemic lupus erythematosus, liver cirrhosis, antiphospholipid syndrome, pseudothrombocytopenia, or drug-induced thrombocytopenia (e.g., due to quinine, heparin, antibiotics, or antiepileptic drugs).
  2. History of any thromboembolic event or extensive/severe bleeding within 1 year prior to the first dose of study drug, such as hemoptysis, major upper gastrointestinal bleeding, intracranial hemorrhage, or presence of sepsis or other irregular bleeding.
  3. Receipt of anti-CD20 monoclonal antibody (e.g., rituximab) or other medicinal treatments (including cyclophosphamide and vindesine) within 3 months prior to the first dose of study drug.
  4. Receipt of the following medicinal treatments within 4 weeks prior to the first dose of study drug: azathioprine, danazol, dapsone, cyclosporine A, tacrolimus, or sirolimus.
  5. Use of anticoagulants or any antiplatelet agents (e.g., aspirin) within 3 weeks prior to the first dose of study drug.
  6. Receipt of emergency treatment for ITP (e.g., methylprednisolone, transfusion, intravenous immunoglobulin, or TPO-RA) within 2 weeks prior to the first dose of study drug.
  7. Splenectomy within 6 months prior to the first dose of study drug.
  8. History of within 5 years prior to screening, with the exception of adequately treated cervical carcinoma in situ, basal cell or squamous cell carcinoma of the skin, localized prostate cancer after radical surgery, ductal carcinoma in situ after radical surgery, or thyroid cancer after radical surgery.
  9. Any unstable systemic disease, including but not limited to: uncontrolled active infection (excluding local infection); unstable angina pectoris; cerebrovascular accident or (within 6 months prior to screening); myocardial infarction or history of coronary angioplasty or stenting (within 6 months prior to screening); (NYHA) Class III or IV cardiac insufficiency; hypertension (defined as blood pressure not controlled after more than 1 month of treatment with ≥ 3 antihypertensive drugs [including diuretics] at reasonable and tolerable doses after lifestyle modification, or requiring ≥ 4 antihypertensive drugs to achieve blood pressure control); severe cardiac arrhythmia requiring medication; or significant hepatic, renal, or metabolic disease.
  10. Known or suspected history of , including invasive opportunistic infections such as histoplasmosis, coccidioidomycosis, coccidiosis, Pneumocystis jirovecii pneumonia, and aspergillosis, even if the infection has resolved; or unusually frequent, recurrent, or prolonged infections, as judged by the investigator.
  11. Positive peripheral blood test for virus (HBV) DNA; positive virus (HCV) antibody with positive peripheral blood HCV RNA; positive (HIV) antibody; positive cytomegalovirus (CMV) DNA; or positive Treponema pallidum test.
  12. Prior receipt of organ transplantation, or planned organ transplantation during the study period.
  13. Prior receipt of CAR-T therapy within 3 months.
  14. Active autoimmune or inflammatory neurological disorder (e.g., Guillain-Barré syndrome, amyotrophic lateral sclerosis).
  15. active cerebrovascular disease (e.g., cerebral edema, posterior reversible encephalopathy syndrome).
  16. of less than 3 months.
  17. Participation in another interventional clinical study and receipt of drug within 1 month prior to enrollment (for marketed drugs, or investigational drugs with a known half-life, the shorter of 5 half-lives or 2 weeks applies).
  18. Receipt of within 6 weeks prior to screening, or planned receipt of live attenuated vaccine during the study period.
  19. or to tocilizumab; contraindication or hypersensitivity to any component of the investigational product, JCXH-213.
  20. Pregnant or lactating women, or women planning to become pregnant or breastfeed from the time of signing the ICF through 6 months after the last infusion of JCXH-213; or male patients whose partner plans to become pregnant during this period.
  21. Any contraindication to any study procedure or other medical condition that, in the investigator's judgment and/or according to clinical standards, would place the patient at unacceptable risk.
Terms in these criteria, in plain language(31)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
4 participants (estimated)

Study arms

  • Experimental
    Dose Level (2 mg,4 mg)

    Drug: JCXH-213

Interventions

  • DrugJCXH-213

    An mRNA-LNP based in vivo CAR therapy

06

What researchers measure

Primary outcomes

  1. Safety and tolerability of JCXH-213

    Number of participants with adverse events (AEs), serious adverse events (SAEs), with abnormal laboratory tests results, abnormal electrocardiogram (ECG) readings, and abnormal vital signs

    Time frame: The DLT observation period is 14 days after the first infusion of JCXH-213 (Day1-Day14).

Secondary outcomes

  1. Platelet count over time

    Platelet count measured at Weeks 1, 2, 4, 8, and Months 3 and 4 after the first JCXH-213 infusion. If platelet count remains ≥ 30 × 10⁹/L at Month 4, extended follow-up may be performed at the investigator's discretion.

    Time frame: Baseline to Month 4 (or longer at investigator's discretion)

  2. Time to platelet response

    Time from first JCXH-213 infusion to first platelet count ≥ 30 × 10⁹/L with ≥ 2-fold increase from baseline, and time to first platelet count ≥ 50 × 10⁹/L.

    Time frame: From first infusion to Day 120

  3. Cumulative weeks of platelet response

    Cumulative weeks with platelet count ≥ 30 × 10⁹/L and ≥ 2-fold increase from baseline, and cumulative weeks with platelet count ≥ 50 × 10⁹/L, from first infusion to Day 120.

    Time frame: From first infusion to Day 120

  4. Change in WHO bleeding score

    Change in World Health Organization (WHO) bleeding score from baseline to Day 56. The WHO bleeding score ranges from 0 to 4, with higher scores indicating worse bleeding outcomes.

    Time frame: Baseline to Day 56

  5. Degree of disease control

    Degree of disease control, defined as cumulative weeks with platelet count ≥ 50 × 10⁹/L over a specified period.

    Time frame: From first infusion to Day 120

  6. Changes in platelet autoantibodies

    Changes in platelet autoantibodies after JCXH-213 infusion, including: (1) quantitative detection of platelet surface-associated immunoglobulins (IgA, IgG, IgM); and (2) qualitative detection of platelet-specific and histocompatibility antibodies.

    Time frame: From first infusion to Day 120

  7. Peripheral blood B-cell subset profiling

    Peripheral blood B-cell subset distribution after JCXH-213 infusion, assessed by flow cytometry.

    Time frame: From first infusion to Day 120

  8. Changes in peripheral blood JCXH-213 mRNA levels

    Changes in peripheral blood JCXH-213 mRNA levels after JCXH-213 infusion, assessed by quantitative PCR (qPCR)

    Time frame: From within 1 hour before the first dose to 24 hours after the last dose (Day 14)

  9. Changes in peripheral blood CD19 CAR-positive cells

    Subset distribution and level changes of peripheral blood CD19 CAR-positive cells after JCXH-213 infusion, assessed by flow cytometry

    Time frame: From within 1 hour before the first dose to 24 hours after the last dose (up to Day 14)

  10. Changes in peripheral blood cytokine levels

    Changes in peripheral blood cytokine levels, including interleukin-6 (IL-6), interferon-α (IFN-α), and interferon-γ (IFN-γ), after JCXH-213 infusion

    Time frame: From within 1 hour before the first dose to 24 hours after the last dose (up to Day 14)

  11. Changes in anti-drug antibodies (ADA)

    Changes in peripheral blood anti-drug antibodies (ADA), including anti-CAR antibodies and anti-PEG antibodies, after JCXH-213 infusion

    Time frame: From within 1 hour before the first dose to 24 hours after the last dose (up to Day 14)

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2026 to primary completion in Sep 2026, 2 months.

Of 27 phase 1 interventional studies under Purpura, Thrombocytopenic, Idiopathic, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 42. This study's 2 months is below that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 17, 2026: primary completion Aug 2026 → Sep 2026 and completion Jun 2027 → Dec 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 21, 2026
First posted
Jun 3, 2026
StartActual
Jun 18, 2026
Primary completionActual
Sep 2, 2026was Aug 2026
CompletionEst.
Dec 30, 2026was Jun 2027
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 17, 2026
Sites
1 site added — first site in China
Show site
  • General Hospital of Western Theater Command of PLA · Chengdu, China
Nov 17, 2026
Primary completion
Aug 30, 2026→Sep 2, 2026 (actual)
Nov 17, 2026
Study completion
Jun 30, 2027→Dec 30, 2026
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    Not yet recruiting→Recruiting
    1 site added — first site in China
    Show site
    • General Hospital of Western Theater Command of PLA · Chengdu, China
    Primary completion Aug 30, 2026→Sep 2, 2026 (now actual)
    Study completion Jun 30, 2027→Dec 30, 2026
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07622329
Lead sponsor
The General Hospital of Western Theater Command
Responsible party
Xiao Wang (Principal Investigator, The General Hospital of Western Theater Command) — Principal investigator
First posted
Jun 3, 2026
Start date
Jun 18, 2026
Primary completion
Sep 2, 2026
Completion
Dec 30, 2026 (estimated)
Last update
Nov 17, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion